NCT06597851 Insulin Resistance and Coronary Microvascular Dysfunction in Patients with Myocardial Ischemia and Non-obstructive Coronary Artery Disease
| NCT ID | NCT06597851 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda Ospedaliera Universitaria Integrata Verona |
| Condition | Coronary Microvascular Dysfunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-06-24 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-06-24 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective study is to assess the correlation between coronary microvascular disfunction and insulin resistance in patients with INOCA. Patients with ANOCA and without diabetes will undergo invasive coronary microvascular assessment through coronary angiography and insulin resistance assessment through hyperinsulinemic-euglycemic clamp test. Patients enrolled in the study will be followed for a period of 2 years to monitor their clinical status.
Eligibility Criteria
Inclusion Criteria: * Aged over 18 years. * Cardiac chest pain with evidence of myocardial ischemia at noninvasive myocardial stress imaging and clinical indication to diagnostic coronary angiography * Willing and able to give informed consent for participation in the study Exclusion Criteria: * Obstructive CAD (defined as more than 70% luminal stenosis and/or FFR ≤0.80 in 1 or more epicardial vessels). * History of previous myocardial infarction, percutaneous revascularization or coronary-aortic bypass graft (CABG) surgery. * Diagnosis of type II diabetes. * BMI ≥ 35 kg/m2. * Stage IV and V of chronic kidney disease (eGFR ≤ 30 ml/min, estimated through CKD - EPI Creatinine Equation). * Allergy or other contraindication to iodinated contrast and/or gadolinium and/or adenosine. * Chronic resting O2 saturation ≤ 85%. * Pregnancy or suspected pregnancy.
Contact & Investigator
Roberto Scarsini MD PhD
PRINCIPAL INVESTIGATOR
Azienda Ospedaliera Universitaria di Verona
Frequently Asked Questions
Who can join the NCT06597851 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Microvascular Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06597851 currently recruiting?
Yes, NCT06597851 is actively recruiting participants. Contact the research team at studi.clinici.cardiologia@aovr.veneto.it for enrollment information.
Where is the NCT06597851 trial being conducted?
This trial is being conducted at Verona, Italy.
Who is sponsoring the NCT06597851 clinical trial?
NCT06597851 is sponsored by Azienda Ospedaliera Universitaria Integrata Verona. The principal investigator is Roberto Scarsini MD PhD at Azienda Ospedaliera Universitaria di Verona. The trial plans to enroll 40 participants.